Advertisement
News
Advertisement

ProLung Names Clark Campbell as Chairman of the Board

Wed, 09/12/2012 - 7:57am
The Associated Press

SALT LAKE CITY--(BUSINESS WIRE)--Sep 12, 2012--The medical technology company ProLung today announced the naming of current board member Clark A. Campbell, Ph.D. as its new Chairman, replacing William A. Fresh, who continues as a Director. Campbell steps into this role as the company makes preparations to market the ProLung Test, a new tool in the early detection of lung cancer. Studies have shown that the test immediately and accurately identifies malignancy in patients who have been found to have an indeterminate lung mass. This can help solve the crucial problem of late detection, a major factor in lung cancer’s high mortality rate.

“Dr. Campbell’s project management expertise will be invaluable as we embark on the final stages of preparing the ProLung Test for U.S. and international markets,” said Steven C. Eror, president and CEO of ProLung. “We’re fortunate to have him join us in our efforts to help give lung cancer patients a better chance for survival.” Clark Campbell is a recognized authority in project management, CEO of OPPM International, and is the award winning author of the highly acclaimed, best-selling One-Page Project ManagerTM series of books published by John Wiley & Sons. He holds a BS in Chemical Engineering, an MBA and a Ph.D. in Business Administration. Clark, a former faculty member at Westminster College and the University of Utah, filled project management positions at the headquarters of the DuPont Chemical Company and senior executive roles at OC Tanner Company in Salt Lake City.

ProLung is a medical technology company committed to promoting lung health and improving outcomes for lung cancer patients. Its management has a collective 40 years of relevant healthcare and biotechnology experience, and its advisory board features world opinion leaders in lung cancer. The testing and devices described herein are investigational, and neither the test nor related statements have been approved by the US FDA. For more information contact info@prolungdx.com or go to www.prolungdx.com.

CONTACT: ProLung Catherine Garff, 801-599-5224 Public Relations ceg@prolungdx.com KEYWORD: UNITED STATES NORTH AMERICA UTAH INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS MEDICAL DEVICES ONCOLOGY RADIOLOGY RESEARCH SCIENCE SOURCE: ProLung Copyright Business Wire 2012 PUB: 09/12/2012 07:57 AM/DISC: 09/12/2012 07:57 AM http://www.businesswire.com/news/home/20120912005926/

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading